All News
COVID-19 and Long-Term Risk of Autoimmune and Autoinflammatory Disorders
A Korean population based study found that people infected with COVID-19, especially severe COVID-19, had an increased risk of autoimmune and autoinflammatory connective tissue disorders.
Read Article
Which One is the Loneliest Number (9.27.2024)
Dr. Jack Cush reviews the regulatory approvals, announcements, guidelines and interesting journal articles from the past week on RheumNow.com. When not to use muscle relaxants, how frequent is loneliness in RA/PsA/SpA, and when to refer patients with Still's disease.
Read Article
EULAR/PReS Still's Disease Management Recommendations
Since 2022, EULAR and the Paediatric Rheumatology European Society (PReS) have been working to establish clinical practice guidelines for the diagnostics and management of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD).
Read Article
I Can't Treat Ugly (9.20.2024)
Dr. Jack Cush reviews the news, journal articles and a new FDA approval for EGPA, this week on the Podcast.
Read Article
If high +ANA and NO #rheumatic #disease LOOK đź‘€ at #LIVER #Autoimmune #hepatitis And #alcoholic #liver #dx #ACRBest #ACR24 @rheumnow abst#0627 https://t.co/EVLUyvpBfD
Links:
Janet Pope Janetbirdope ( View Tweet)
CV risk factors in rheumatic dz patients start in childhood. Patients with PMH of Kawasaki disease are at risk for rca/lmca aneurysms, thrombosis and stroke. Important to consider this with our history taking when pediatric patients transition to adult care! @RheumNow #ACR24 https://t.co/CIp8PjW4vD
Gabriela Martinez Zayas, MD MartinezZayasMd ( View Tweet)
Diagnosis and Management of Kawasaki Disease
The journal Circulation has published a comprehensive overview called “Update on Diagnosis and Management of Kawasaki Disease,” summarizing data published since the 2017 American Heart Association Scientific Statement on Kawasaki… https://t.co/rS5bDneplO https://t.co/nZ0GeIQD0T
Dr. John Cush RheumNow ( View Tweet)
COVID-19 and Long-Term Risk of Autoimmune and Autoinflammatory Disorders
A Korean population based study found that people infected with COVID-19, especially severe COVID-19, had an increased risk of autoimmune and autoinflammatory connective tissue disorders.… https://t.co/zlJrusJDM4 https://t.co/cuumClbN6b
Dr. John Cush RheumNow ( View Tweet)
New download available!
Substitute Inflammatory Measures
https://t.co/FiZSvvl5DA https://t.co/QwVefFLcHO
Dr. John Cush RheumNow ( View Tweet)
A Keto Diet for Autoimmune Disorders?
Scientists have long suspected the keto diet might be able to calm an overactive immune system and help some people with diseases like multiple sclerosis.
https://t.co/7mX6Ue4FdX https://t.co/qtOwdKfqu4
Dr. John Cush RheumNow ( View Tweet)
Trends in DMARD Use in Juvenile Arthritis 2001-2022
Arthritis & Rheumatology reports that treatment trends in juvenile idiopathic arthritis (JIA) in the last two decades finds rising use of newer biologic and targeted synthetic DMARDs coupled with a decline in conventional… https://t.co/fEOvjm21lY https://t.co/LfDleabEQS
Dr. John Cush RheumNow ( View Tweet)
Nailfold videocapillaroscopy (NVC) study of 65 Behcets pts found vascular abnl in 40-47% ( enlarged/tortuous capillaries, microhaemorrhages. Having ≥2 NVC abnormalities increase risk of Vascular events (VTE, superficial thrombophlebitis), but not ANA https://t.co/2Om0IIFVnG https://t.co/W7mbdPh9ee
Dr. John Cush RheumNow ( View Tweet)
Long-term Tofacitinib in Juvenile Idiopathic Arthritis
The long-term safety and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) has been established in an ongoing long term extension (LTE) study.
https://t.co/IKHM6z8iMB https://t.co/O6ig1lTQR4
Dr. John Cush RheumNow ( View Tweet)
#VEXAS can present as atypical &/or refractory #ANCA-associated #vasculitis
Consider possibility of VEXAS in cases of AAV
▶️Refractory to multiple treatment
▶️Atypical kidney biopsy
👉🏽https://t.co/1Vewb5n5vZ
via @RheumJnl https://t.co/FLov5xaQAA
Links:
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
Mucosal Disruptions as Initiators of Rheumatoid Arthritis
The microbiome and mucosal disruptions are believed to play a role in autoimmunity, particularly rheumatoid arthritis (RA). This is linked to the "mucosal hypothesis" of RA. A recent review by Hollers, et al. discusses… https://t.co/79khnkajMy https://t.co/UvZWwJ3ERg
Dr. John Cush RheumNow ( View Tweet)
JCI article on Mechanisms underlying sex differences in autoimmunity - factors include sex hormones, X chromosome genes, sex-specific epigenetic effects of estrogen & environment, and microRNA effects. Also mitochondria & autoantibodies discussed https://t.co/hTrizE8jFK https://t.co/VixAZsYBzb
Dr. John Cush RheumNow ( View Tweet)
Full read review of Pathogenic autoantibodies in idiopathic inflammatory myopathies: antisynthetase autoAbs, TIF1, MDA5, SRP, HMGCR, TRIM72, cN1A, FHL1, eIF3 autoantibodies and more https://t.co/uzCmauulWZ https://t.co/twhwCB4xof
Dr. John Cush RheumNow ( View Tweet)
British Society Guidelines for Managing Behçet’s Disease
An exhaustive, full read guideline from the British Association of Dermatologists (BAD) and the British Society for Rheumatology (BSR) on the management and treatment of Behçet’s disease (BD) in 2024 has been published in… https://t.co/4Q1Ac60Dyp https://t.co/Qj3sQQ8SnJ
Dr. John Cush RheumNow ( View Tweet)
EULAR/PReS Still's Disease Management Recommendations
Since 2022, EULAR and the Paediatric Rheumatology European Society (PReS) have been working to establish clinical practice guidelines for the diagnostics and management of systemic juvenile idiopathic arthritis (sJIA) and… https://t.co/JZidoWEZSq https://t.co/miwnaw5BZ3
Dr. John Cush RheumNow ( View Tweet)
Chinese study of 62 Systemic JIA pts Rx w/ IV Tocilizumab (34 12 mg/kg; 28 8 mg/kg). Wk12 87% responded (JIA ACR 30w/ no fever); Week 52 results were similar. No deaths or macrophage activation syndrome occurred. https://t.co/qGgMCt597x https://t.co/lFDxAgDHfW
Dr. John Cush RheumNow ( View Tweet)
